The Etro Studies
Passionate Professionals. Determined to Make a Difference.
Our research team here at Genentech provides a solid foundation for the Etro Studies. Genentech has an extensive track record for bringing innovative new disease treatments to patients with serious or life-threatening medical conditions.
Founded in 1976, we have focused our drug discovery efforts on monoclonal antibodies, small molecules, and antibody-drug conjugates that address significant unmet need. We believe a treatment for Ulcerative Colitis and Crohn’s is one of those needs.
We use an extensive set of criteria, including scientific rationale and medical need, to determine which projects to move from discovery research into development.
Our clinical scientists and medical professionals help us determine which investigational drugs are tested against specific diseases in the clinic and guide chosen investigational drugs through the many phases of clinical testing.
Our belief in these studies
We are focused on investigating the proposed dual mechanism of action in etrolizumab for the treatment of Ulcerative Colitis and Crohn’s to determine whether the investigational drug can inhibit both lymphocyte trafficking to the gut mucosa and the retention of lymphocytes in the intraepithelial space.
Our standard of care
Scientists at Genentech are always exploring new approaches to understanding the basic biology of particular diseases and to identify biomarkers that reveal cellular pathways that are critical for the progression of these diseases.1
1. Gene Expressions: Understanding Biomarkers. Accessed May 7, 2014.